CA3049967C - Therapeutic anti-ige antibodies and methods and compositions thereof - Google Patents

Therapeutic anti-ige antibodies and methods and compositions thereof

Info

Publication number
CA3049967C
CA3049967C CA3049967A CA3049967A CA3049967C CA 3049967 C CA3049967 C CA 3049967C CA 3049967 A CA3049967 A CA 3049967A CA 3049967 A CA3049967 A CA 3049967A CA 3049967 C CA3049967 C CA 3049967C
Authority
CA
Canada
Prior art keywords
compositions
ige
therapies
associated methods
ige antibodies
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CA3049967A
Other languages
English (en)
French (fr)
Other versions
CA3049967A1 (en
Inventor
Andrew Saxon
Ke Zhang
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sixal Inc
University of California Berkeley
University of California San Diego UCSD
Original Assignee
Sixal Inc
University of California Berkeley
University of California San Diego UCSD
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=62789396&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CA3049967(C) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Sixal Inc, University of California Berkeley, University of California San Diego UCSD filed Critical Sixal Inc
Publication of CA3049967A1 publication Critical patent/CA3049967A1/en
Application granted granted Critical
Publication of CA3049967C publication Critical patent/CA3049967C/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/42—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins
    • C07K16/4283—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an allotypic or isotypic determinant on Ig
    • C07K16/4291—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an allotypic or isotypic determinant on Ig against IgE
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pulmonology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Transplantation (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
CA3049967A 2017-01-06 2018-01-05 Therapeutic anti-ige antibodies and methods and compositions thereof Active CA3049967C (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762443547P 2017-01-06 2017-01-06
US62/443,547 2017-01-06
PCT/US2018/012479 WO2018129248A1 (en) 2017-01-06 2018-01-05 Therapeutic anti-ige antibodies and methods and compositions thereof

Publications (2)

Publication Number Publication Date
CA3049967A1 CA3049967A1 (en) 2018-07-12
CA3049967C true CA3049967C (en) 2024-10-01

Family

ID=62789396

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3049967A Active CA3049967C (en) 2017-01-06 2018-01-05 Therapeutic anti-ige antibodies and methods and compositions thereof

Country Status (6)

Country Link
US (2) US11518818B2 (enExample)
EP (1) EP3565587A4 (enExample)
JP (2) JP7128191B2 (enExample)
AU (1) AU2018205484B2 (enExample)
CA (1) CA3049967C (enExample)
WO (1) WO2018129248A1 (enExample)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113474012B (zh) 2019-01-25 2023-09-08 湖南远泰生物技术有限公司 Epcam抗体和epcam-car-t细胞

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2193136T3 (es) * 1991-08-14 2003-11-01 Genentech Inc Variantes de inmunoglubina para receptores especificos de fc epsilon.
US6699472B2 (en) 1991-08-14 2004-03-02 Genentech, Inc. Method of treating allergic disorders
CN1418222A (zh) 2000-01-14 2003-05-14 第一制药株式会社 新的肽以及使用该肽的筛选方法
AU7658101A (en) 2000-07-28 2002-02-13 Cytos Biotechnology Ag Compositions for inducing self-specific anti-ige antibodies and uses thereof
SI2407485T1 (sl) * 2003-02-01 2016-09-30 Tanox, Inc. Visoko afinitetna anti-humana protitelesa IgE
US20050169909A1 (en) * 2004-02-02 2005-08-04 Sanjaya Singh Identification of novel IgE epitopes
CN102702359A (zh) 2004-02-02 2012-10-03 泰勒公司 新的IgE表位的鉴别
EP2511299A1 (en) * 2005-04-19 2012-10-17 Seattle Genetics, Inc. Humanized anti-CD70 binding agents and uses thereof
ES2523915T5 (es) 2006-12-01 2022-05-26 Seagen Inc Agentes de unión a la diana variantes y usos de los mismos
US7867494B2 (en) 2007-04-02 2011-01-11 Amgen Fremont Inc. Anti-IgE antibodies
US8043620B2 (en) * 2007-11-21 2011-10-25 Amgen Inc. Wise binding agents and epitopes
CN103459422A (zh) * 2010-11-24 2013-12-18 葛兰素集团有限公司 靶向hgf的多特异性抗原结合蛋白
JP2015506950A (ja) 2012-01-31 2015-03-05 ジェネンテック， インコーポレイテッド 抗ｉｇ−ｅｍ１’抗体およびそれを用いる方法
WO2013192594A2 (en) * 2012-06-21 2013-12-27 Sorrento Therapeutics Inc. Antigen binding proteins that bind c-met
TWI542598B (zh) * 2014-06-17 2016-07-21 中央研究院 交聯B淋巴球之CD23但不致敏肥大細胞的人源化抗-IgE抗體
WO2017186928A1 (en) 2016-04-29 2017-11-02 Curevac Ag Rna encoding an antibody
US11326182B2 (en) 2016-04-29 2022-05-10 Voyager Therapeutics, Inc. Compositions for the treatment of disease
EP3744734A1 (en) * 2018-01-22 2020-12-02 Jiangsu Hengrui Medicine Co., Ltd. Anti-4-1bb antibody, antigen-binding fragment thereof and medical use thereof

Also Published As

Publication number Publication date
US20230090487A1 (en) 2023-03-23
JP7461420B2 (ja) 2024-04-03
US11518818B2 (en) 2022-12-06
WO2018129248A1 (en) 2018-07-12
JP2022172170A (ja) 2022-11-15
US20190322766A1 (en) 2019-10-24
CA3049967A1 (en) 2018-07-12
AU2018205484B2 (en) 2024-11-21
EP3565587A1 (en) 2019-11-13
EP3565587A4 (en) 2020-12-16
JP7128191B2 (ja) 2022-08-30
AU2018205484A1 (en) 2019-08-01
JP2020505334A (ja) 2020-02-20

Similar Documents

Publication Publication Date Title
WO2018069500A3 (en) Anti-lag-3 antibodies and compositions
EA201990004A1 (ru) АНТИ-IgE АНТИТЕЛА
EA201691877A1 (ru) Человеческие антитела к спайк-белку коронавируса ближневосточного респираторного синдрома
CR20210176A (es) Anticuerpos estabilizadores de trem2
EA201890453A1 (ru) Анти-angptl8 антитела и их применение
MA45235B1 (fr) Anticorps anti-c5 et leurs utilisations
BR112022009317A2 (pt) Anticorpos de cd73 biparatópicos
MX2022002682A (es) Anticuerpos anti-cd73.
NZ758301A (en) Anti-trem2 antibodies and methods of use thereof
EA201290589A1 (ru) Cd127-связывающие белки
MX2022004072A (es) Anticuerpos de factor xi y metodos de uso.
MY189159A (en) Multispecific antigen-binding molecules and uses thereof
WO2020006374A3 (en) Anti-sirp-beta1 antibodies and methods of use thereof
PH12015501656B1 (en) Anti-il-33 antibodies and use thereof
PH12019501387A1 (en) Anti-cd3 antibody and molecules comprising the antibody
MX2020008736A (es) Formulaciones de anticuerpos b7-h4.
EA202190162A3 (ru) Способы лечения заболеваний, при которых активность il-13 оказывает негативное влияние, с применением антител против il-13
EA202092518A1 (ru) Композиции и способы лечения рака
MY184189A (en) Methods of treating nail and scalp psoriasis
HK1220707A1 (zh) 凝集素样氧化的ldl受体1抗体和使用方法
MX2021006362A (es) Anticuerpos de dominio simple contra cll-1.
WO2020089396A3 (en) Composition and methods of treating inflammatory and autoimmune diseases
EA201992626A1 (ru) Способы и композиции для лечения аллергических заболеваний глаз
MX2020009496A (es) Metodo para tratar asma o enfermedad alergica.
CA3049967C (en) Therapeutic anti-ige antibodies and methods and compositions thereof

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20220802

EEER Examination request

Effective date: 20220802

EEER Examination request

Effective date: 20220802

EEER Examination request

Effective date: 20220802

EEER Examination request

Effective date: 20220802

EEER Examination request

Effective date: 20220802

EEER Examination request

Effective date: 20220802

EEER Examination request

Effective date: 20220802

EEER Examination request

Effective date: 20220802

EEER Examination request

Effective date: 20220802